Advertisement

Latest News

Single-Day GH001 for TRD Shows Rapid Response, With Michael E. Thase, PhD

21 minutes ago

An interview with Thase explores rapid antidepressant effects and real-world considerations for single-day individualized GH001 dosing in TRD.

AAD 2026: Owning Psoriatic Disease, With Lindsay Ackerman, MD

3 hours ago

Ackerman offers a broad perspective on how psoriatic treatment is shifting, from oral IL-23 inhibitors to the emerging role of incretin therapy in psoriatic disease.

Disease Mechanisms, Emerging Therapies, and Reducing Corticosteroid Reliance in CSU

3 hours ago

Experts examine CSU endotypes and their implications for treatment selection and preview the emerging therapeutic pipeline including barzolvolimab and novel mast cell–depleting strategies.

Lebrikizumab for Atopic Dermatitis Leads to 4 Years of Clearance, Itch Reduction

4 hours ago

The durability of both skin clearance and itch reduction extended up to 4 years of lebrikizumab use in this assessment of adults and adolescents with atopic dermatitis.

ABCs in Dermatology: Late Breaking Data Spotlight at AAD 2026

14 hours ago

Late-breaking AAD 2026 trials spotlight PsA weight-loss combo, twice-yearly IL-13 dosing for atopic dermatitis, and a rapid oral TYK2 pill for psoriasis.

Advertisement
Advertisement